These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
689 related articles for article (PubMed ID: 19711346)
1. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Zhu Z; Hao X; Yan M; Yao M; Ge C; Gu J; Li J Int J Cancer; 2010 May; 126(9):2067-78. PubMed ID: 19711346 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of the expression of cancer stem cell-related markers CD133 and CD44 in hepatocellular carcinoma: From patients to patient-derived tumor xenograft models. Zhao Q; Zhou H; Liu Q; Cao Y; Wang G; Hu A; Ruan L; Wang S; Bo Q; Chen W; Hu C; Xu D; Tao F; Cao J; Ge Y; Yu Z; Li L; Wang H Oncotarget; 2016 Jul; 7(30):47431-47443. PubMed ID: 27329727 [TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Ma S; Chan KW; Hu L; Lee TK; Wo JY; Ng IO; Zheng BJ; Guan XY Gastroenterology; 2007 Jun; 132(7):2542-56. PubMed ID: 17570225 [TBL] [Abstract][Full Text] [Related]
4. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma. Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240 [TBL] [Abstract][Full Text] [Related]
5. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Ma S; Chan KW; Lee TK; Tang KH; Wo JY; Zheng BJ; Guan XY Mol Cancer Res; 2008 Jul; 6(7):1146-53. PubMed ID: 18644979 [TBL] [Abstract][Full Text] [Related]
6. Patients with CD133-negative colorectal liver metastasis have a poor prognosis after hepatectomy. Yamamoto S; Tanaka K; Takeda K; Akiyama H; Ichikawa Y; Nagashima Y; Endo I Ann Surg Oncol; 2014 Jun; 21(6):1853-61. PubMed ID: 24554065 [TBL] [Abstract][Full Text] [Related]
7. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564 [TBL] [Abstract][Full Text] [Related]
8. Surface markers of hepatocellular cancer stem cells and their clinical potential. Feng D; Wang N; Hu J; Li W Neoplasma; 2014; 61(5):505-13. PubMed ID: 24712843 [TBL] [Abstract][Full Text] [Related]
9. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells. Jia Q; Zhang X; Deng T; Gao J Cell Reprogram; 2013 Apr; 15(2):143-50. PubMed ID: 23438193 [TBL] [Abstract][Full Text] [Related]
10. CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma. Shi C; Tian R; Wang M; Wang X; Jiang J; Zhang Z; Li X; He Z; Gong W; Qin R Cancer Biol Ther; 2010 Dec; 10(11):1182-90. PubMed ID: 20948317 [TBL] [Abstract][Full Text] [Related]
11. Expansion and characterization of cancer stem-like cells in squamous cell carcinoma of the head and neck. Okamoto A; Chikamatsu K; Sakakura K; Hatsushika K; Takahashi G; Masuyama K Oral Oncol; 2009 Jul; 45(7):633-9. PubMed ID: 19027347 [TBL] [Abstract][Full Text] [Related]
12. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Ma S; Lee TK; Zheng BJ; Chan KW; Guan XY Oncogene; 2008 Mar; 27(12):1749-58. PubMed ID: 17891174 [TBL] [Abstract][Full Text] [Related]
13. The CD133+ subpopulation of the SW982 human synovial sarcoma cell line exhibits cancer stem-like characteristics. Liu A; Feng B; Gu W; Cheng X; Tong T; Zhang H; Hu Y Int J Oncol; 2013 Apr; 42(4):1399-407. PubMed ID: 23416969 [TBL] [Abstract][Full Text] [Related]
14. Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+/CD44+ cancer stem cells to 5 azacytidine in hepatocellular carcinoma. Gao X; Sheng Y; Yang J; Wang C; Zhang R; Zhu Y; Zhang Z; Zhang K; Yan S; Sun H; Wei J; Wang X; Yu X; Zhang Y; Luo Q; Zheng Y; Qiao P; Zhao Y; Dong Q; Qin L J Exp Clin Cancer Res; 2018 Jul; 37(1):179. PubMed ID: 30064482 [TBL] [Abstract][Full Text] [Related]
15. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Suetsugu A; Nagaki M; Aoki H; Motohashi T; Kunisada T; Moriwaki H Biochem Biophys Res Commun; 2006 Dec; 351(4):820-4. PubMed ID: 17097610 [TBL] [Abstract][Full Text] [Related]
16. Investigation of diagnostic utility and expression profiles of stem cell markers (CD133 and CD90) in hepatocellular carcinoma, small cell dysplasia, and cirrhosis. Yilmaz G; Akyol G; Cakir A; Ilhan M Pathol Res Pract; 2014 Jul; 210(7):419-25. PubMed ID: 24702884 [TBL] [Abstract][Full Text] [Related]
17. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. Kim MP; Fleming JB; Wang H; Abbruzzese JL; Choi W; Kopetz S; McConkey DJ; Evans DB; Gallick GE PLoS One; 2011; 6(6):e20636. PubMed ID: 21695188 [TBL] [Abstract][Full Text] [Related]
18. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. Zhang J; Luo N; Luo Y; Peng Z; Zhang T; Li S Int J Oncol; 2012 Mar; 40(3):747-56. PubMed ID: 22025269 [TBL] [Abstract][Full Text] [Related]
19. A Novel Function for KLF4 in Modulating the De-differentiation of EpCAM Karagonlar ZF; Akbari S; Karabicici M; Sahin E; Avci ST; Ersoy N; Ates KE; Balli T; Karacicek B; Kaplan KN; Celiker C; Atabey N; Erdal E Cells; 2020 May; 9(5):. PubMed ID: 32408542 [TBL] [Abstract][Full Text] [Related]
20. Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Ji J; Wang XW Semin Oncol; 2012 Aug; 39(4):461-72. PubMed ID: 22846863 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]